中华内科杂志
中華內科雜誌
중화내과잡지
CHINESE JOURNAL OF INTERNAL MEDICINE
2011年
4期
295-298
,共4页
肺炎,吸入性%头孢美唑%治疗效果%安全
肺炎,吸入性%頭孢美唑%治療效果%安全
폐염,흡입성%두포미서%치료효과%안전
Pneumonia,aspiration%Cefmetazole%Treatment outcome%Safety
目的 评价头孢美唑治疗吸入性肺炎的临床疗效与安全性.方法 采用多中心、前瞻性、开放性临床研究.共入选1522例吸入性肺炎患者,静脉滴注头孢美唑2.0 g、2次/d,疗程7～14 d.记录观察期间出现的药物不良反应,评估治疗结束时的临床疗效、细菌学疗效及安全性.结果 33家医院参加了本研究,共入选1522例患者.符合意向性分析1522例,其中198例因违反试验方案、疗程资料缺失、患者依从性差及中途停药等原因剔除,最终符合方案集分析1324例.头孢美唑治疗1324例患者痊愈690例,显效366例,总有效率为79.8%(1056/1324).细菌学清除率为75.0%(342/456),头孢美唑对肺炎克雷伯杆菌、大肠埃希菌、甲氧西林敏感的金黄色葡萄球菌及厌氧菌的清除率分别是78.2%(97/124)、80.8%(80/99)、89.0%(81/91)和9/11.不良反应以肖化系统反应比较常见,主要有轻度恶心、呕吐、腹泻、头晕、皮疹、ALT一过性升高,停药后均好转.不良反应发生率为1.7%(26/1552).结论 头孢美唑治疗吸入性肺炎疗效好,安全性高.
目的 評價頭孢美唑治療吸入性肺炎的臨床療效與安全性.方法 採用多中心、前瞻性、開放性臨床研究.共入選1522例吸入性肺炎患者,靜脈滴註頭孢美唑2.0 g、2次/d,療程7～14 d.記錄觀察期間齣現的藥物不良反應,評估治療結束時的臨床療效、細菌學療效及安全性.結果 33傢醫院參加瞭本研究,共入選1522例患者.符閤意嚮性分析1522例,其中198例因違反試驗方案、療程資料缺失、患者依從性差及中途停藥等原因剔除,最終符閤方案集分析1324例.頭孢美唑治療1324例患者痊愈690例,顯效366例,總有效率為79.8%(1056/1324).細菌學清除率為75.0%(342/456),頭孢美唑對肺炎剋雷伯桿菌、大腸埃希菌、甲氧西林敏感的金黃色葡萄毬菌及厭氧菌的清除率分彆是78.2%(97/124)、80.8%(80/99)、89.0%(81/91)和9/11.不良反應以肖化繫統反應比較常見,主要有輕度噁心、嘔吐、腹瀉、頭暈、皮疹、ALT一過性升高,停藥後均好轉.不良反應髮生率為1.7%(26/1552).結論 頭孢美唑治療吸入性肺炎療效好,安全性高.
목적 평개두포미서치료흡입성폐염적림상료효여안전성.방법 채용다중심、전첨성、개방성림상연구.공입선1522례흡입성폐염환자,정맥적주두포미서2.0 g、2차/d,료정7～14 d.기록관찰기간출현적약물불량반응,평고치료결속시적림상료효、세균학료효급안전성.결과 33가의원삼가료본연구,공입선1522례환자.부합의향성분석1522례,기중198례인위반시험방안、료정자료결실、환자의종성차급중도정약등원인척제,최종부합방안집분석1324례.두포미서치료1324례환자전유690례,현효366례,총유효솔위79.8%(1056/1324).세균학청제솔위75.0%(342/456),두포미서대폐염극뢰백간균、대장애희균、갑양서림민감적금황색포도구균급염양균적청제솔분별시78.2%(97/124)、80.8%(80/99)、89.0%(81/91)화9/11.불량반응이초화계통반응비교상견,주요유경도악심、구토、복사、두훈、피진、ALT일과성승고,정약후균호전.불량반응발생솔위1.7%(26/1552).결론 두포미서치료흡입성폐염료효호,안전성고.
Objective To evaluate the efficacy and safety of intravenous cefmetazole in the treatment of patients with aspiratory pneumonia. Methods A multicenter, prospective and open-labeled trial was conducted. A total of 1522 patients were enrolled at the beginning, and only 1324 were evaluabled at the endpoint. The duration of treatment was 7-14 days. During the treatment and follow-up periods, we recorded any unexpected symptoms and abnormal laboratory tests. At last,we evaluated its efficacy and safety. Results The total effective rate of cefmetazole was 79. 8% (1056/1324). The total bacterial eradication rate was 75.0% ( 342/456 ) . The bacterial eradication rates of klebsiellar pneumonia, escherichia, staphyloccocus aureus and anaerobic bacteria were 78.2% (97/124), 80.8% (80/99), 89.0% (81/91), 9/11,respectively. Conclusions Cefmetazole is effective and safe in the treatment of aspiratory pneumonia.
